Literature DB >> 12619165

De novo erythroleukemia chromosome features include multiple rearrangements, with special involvement of chromosomes 11 and 19.

Juan C Cigudosa1, Maria D Odero, M José Calasanz, Francesc Solé, Marta Salido, Eva Arranz, Angel Martínez-Ramirez, Miguel Urioste, Sara Alvarez, Jose V Cervera, Donald MacGrogan, Miguel A Sanz, Stephen D Nimer, Javier Benitez.   

Abstract

Erythroid leukemia (ERL or AML-M6) is an uncommon subtype of acute myeloid leukemia, the clinical, morphological, and genetic behavior of which needs further characterization. We analyzed a homogeneous group of 23 de novo AML-M6 patients whose bone marrow cells showed complex karyotypes. We also analyzed eight leukemia cell lines with erythroid phenotype, performing detailed molecular cytogenetic analyses, including spectral karyotyping (SKY) in all samples. The main features are: (1) A majority of patients (56%) had hypodiploidy. Loss of genetic material was the most common genetic change, especially monosomies of chromosome 7 or 18, and deletions of chromosome arm 5q. Taken together, 87% of the cases displayed aberrations involving chromosome 5 or 8. (2) We describe a novel, cryptic, and recurrent translocation, t(11;19)(p11.2;q13.1). Another translocation, t(12;21)(p11.2;q11.2), was found to be recurrent in a patient with ERL and in the K562 cell line. (3) MLL gene rearrangements were detected in 20% of cases (three translocations and three amplifications) and, overall, we defined 52 rearrangements (excluding deletions) with a mean of 2.3 translocations per patient. (4) Of the structural aberrations, 21% involved chromosomes 11 and 19. Most of the rearrangements were unbalanced; only 13 reciprocal translocations were observed. The general picture of chromosomal aberrations in cell lines did not reflect what occurred in patient samples. However, both primary samples and cell lines shared three common breakpoints at 19q13.1, 20q11.2, and 21q11.2. This is the first molecular cytogenetic description of the karyotype abnormalities present in patients with ERL. It should assist in the identification of genes involved in erythroleukemogenesis. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12619165     DOI: 10.1002/gcc.10180

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  6 in total

Review 1.  Double minutes, cytogenetic equivalents of gene amplification, in human neoplasia - a review.

Authors:  Erich Gebhart
Journal:  Clin Transl Oncol       Date:  2005-12       Impact factor: 3.405

Review 2.  Molecular cytogenetics in translational oncology: when chromosomes meet genomics.

Authors:  M J Calasanz; J C Cigudosa
Journal:  Clin Transl Oncol       Date:  2008-01       Impact factor: 3.405

Review 3.  Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype.

Authors:  Krzysztof Mrózek
Journal:  Semin Oncol       Date:  2008-08       Impact factor: 4.929

4.  Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.

Authors:  F P S Santos; S Faderl; G Garcia-Manero; C Koller; M Beran; S O'Brien; S Pierce; E J Freireich; X Huang; G Borthakur; C Bueso-Ramos; M de Lima; M Keating; J Cortes; H Kantarjian; F Ravandi
Journal:  Leukemia       Date:  2009-09-10       Impact factor: 11.528

5.  Robust CRISPR/Cas9 Genome Editing of the HUDEP-2 Erythroid Precursor Line Using Plasmids and Single-Stranded Oligonucleotide Donors.

Authors:  Gemma Moir-Meyer; Pak Leng Cheong; Aude-Anais Olijnik; Jill Brown; Samantha Knight; Andrew King; Ryo Kurita; Yukio Nakamura; Richard J Gibbons; Douglas R Higgs; Veronica J Buckle; Christian Babbs
Journal:  Methods Protoc       Date:  2018-07-30

6.  NKL Homeobox Genes NKX2-3 and NKX2-4 Deregulate Megakaryocytic-Erythroid Cell Differentiation in AML.

Authors:  Stefan Nagel; Claudia Pommerenke; Corinna Meyer; Roderick A F MacLeod
Journal:  Int J Mol Sci       Date:  2021-10-22       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.